References
Neutropenic sepsis: preventing an avoidable tragedy
Abstract
Neutropenic sepsis is a life-threatening side-effect of chemotherapy—patients are still dying from this complication of treatment, and these deaths are largely preventable. The purpose of this article is to raise awareness of the condition, its severity and the importance of timely responses to it. The main issue for prehospital clinicians is that symptoms of neutropenic sepsis, especially in the early stages, are so vague that they are easily misinterpreted or dismissed as opposed to being indicative of a time-critical patient. The patient's history is of paramount importance in identifying patients in the community that are vulnerable to the condition—those recovering from chemotherapy. These patients are highly prone to infection and are temporarily immune compromized due to the medications that they have been prescribed. They are incapable of mounting a response to infection and infective agents can overwhelm them rapidly. It is imperative in this patient group to have a high degree of suspicion about ‘simple’ assessment findings and non-specific symptoms as these can progress very quickly to haemodynamic collapse and death. Timely hospital-directed antibiotic therapy and support can prevent this possible tragedy.
Over the last decade, major improvements have been made in the treatment of cancer. The NHS Cancer Plan (Department of Health (DH), 2000) has assisted this by providing structure and funding to improve cancer services throughout England.
Chemotherapy, the use of cytotoxic medications, is one of the essential treatments available for cancer. There has been an exponential increase in the use of chemotherapies for a wide range of tumour sites—in fact, the list of chemotherapy resistant cancers is rapidly diminishing due to the development of new and effective drug therapies (Demetri et al, 2002; Goldman, 2003).
Over the years, chemotherapy treatments for advanced metastatic cancer have also improved which is resulting in patients receiving an increasing number of courses of treatment. Adjuvant chemotherapy has become more aggressive, with dose escalation and accelerated regimes being offered in trial settings.
Subscribe to get full access to the Journal of Paramedic Practice
Thank you for visiting the Journal of Paramedic Practice and reading our archive of expert clinical content. If you would like to read more from the only journal dedicated to those working in emergency care, you can start your subscription today for just £48.
What's included
-
CPD Focus
-
Develop your career
-
Stay informed